All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2017; the latest 2025-03-19.
From the record
ImmunityBio, Inc.'s filings since 2017 show 1 warning event: an auditor change (8-K item 4.01, the latest 2025-03-19) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+139.3% a year over 10 filed years; profitable in 0 of 10.
From the record
ImmunityBio, Inc.'s 10 filed years say what it did: revenue went from $44 thousand in fiscal 2016 to $113 million in fiscal 2025, up 139.3% a year; it rose in 7 of 9 years; the deepest fall was 89% from fiscal 2019 to fiscal 2022; net income was positive in 0 of 10 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 3.7/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: ImmunityBio, Inc.'s shareholder treatment is put at 3.7 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 37% of 146 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
Leverage 200%: owes 200¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, ImmunityBio, Inc.'s shareholders' equity was below zero, so the profit on it is not read, and gross profitability: its products earned about 22 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 200 cents per dollar of assets, and net share issuance: its share count grew 31.3% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 28% of 102 in its family; net margin -310.2%.
From the record
ImmunityBio, Inc.'s standing among 102 graded names in its industry family: revenue of $113 million in fiscal 2025 ranks in the top 28% by size; a net margin of -310.2% ranks in the bottom 48%; revenue growth of 678.3% a year over the last 3 filed years ranks in the top 2% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
top 42% of 110 in its family for leadership; chief executive since 2020.
From the record
ImmunityBio, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Adcock, Richard (CEO & President, as filed), filing under that title since 2020-10-29, 6 years (top 36% of its family); the 11 officers and directors filing in the last fifteen months have been on the record a median of 5.7 years (top 43%); 5 officer or director changes were reported on Form 8-K since 2023-11-13, against the 11 people in charge now (top 47%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
top 44% of 92 in its family for room to expand.
From the record
ImmunityBio, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $88 million against no long-term debt tagged leaves 17.6% of its assets as net cash, bottom 31% of its family; cash from operations less capital spending is -272.6% of revenue (bottom 47%); a gross margin of 99.3% (top 10%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 35% of 100 in its family for growth drivers.
From the record
ImmunityBio, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 678.3% a year over the last three filed years against 139.3% over all 10, speeding up (top 1% of its family); the newest year grew 669.4% (top 5%); research spending grew -1% a year (bottom 46%); capital spending grew -63.3% a year (bottom 19%) (its annual reports). ImmunityBio, Inc. reported 2 product lines in fiscal 2025: Product at $113 million (100%), Product and Service Other at $306 thousand (0%); 1 of 2 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 32% of 72 in its family for expectations against reality.
From the record
ImmunityBio, Inc.'s newest year against its own record: revenue of $113 million in fiscal 2025 came in 1.8% below the $115 million its prior three years' pace pointed to (bottom 47% of its family); net income of $351 million against a prior three-year average of $471 million (top 40%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 2%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made